Blog
Earnings Preview: Lundin Mining (LUNMF) Q2 Earnings Expected to Decline
Wall Street expects a year-over-year decline in earnings on lower revenues when Lundin Mining (LUNMF) reports results for the quarter ended June 2025. While this widely-known consensus outlook is
Unity Software Inc. (U) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Unity Software Inc. (U) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook
Vital Energy (VTLE) Earnings Expected to Grow: Should You Buy?
The market expects Vital Energy (VTLE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus
A.P. Moller-Maersk (AMKBY) Expected to Beat Earnings Estimates: Should You Buy?
The market expects A.P. Moller-Maersk (AMKBY) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus
Uber Technologies (UBER) Earnings Expected to Grow: Should You Buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Uber Technologies (UBER) reports results for the quarter ended June 2025. While this widely-known consensus outlook
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
The market expects Vertex (VERX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is
Trimble Navigation (TRMB) Reports Next Week: Wall Street Expects Earnings Growth
Wall Street expects a year-over-year increase in earnings on lower revenues when Trimble Navigation (TRMB) reports results for the quarter ended June 2025. While this widely-known consensus outlook
Here's What Key Metrics Tell Us About Sleep Number (SNBR) Q2 Earnings
Sleep Number (SNBR) reported $327.93 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 19.7%. EPS of -$1.09 for the same period compares to -$0.22 a year
Fortive (FTV) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Fortive (FTV) reported $1.02 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 34.5%. EPS of $0.58 for the same period compares to $0.93 a year ago.
The
Compared to Estimates, Redwood Trust (RWT) Q2 Earnings: A Look at Key Metrics
For the quarter ended June 2025, Redwood Trust (RWT) reported revenue of $13.8 million, down 45.5% over the same period last year. EPS came in at $0.18, compared to $0.13 in the year-ago quarter.
Best Momentum Stocks to Buy for July 30th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 30th:
Boyd Gaming Corporation BYD: This gaming company has a Zacks Rank #1 and witnessed
Microsoft to Report Fiscal Q4 Earnings Today: ETFs to Watch
Microsoft MSFT is set to release its fourth-quarter fiscal 2025 results today after market close. It is worth taking a look at this leading software company’s fundamentals ahead of its results
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
Shares of Novo Nordisk NVO plunged 21.8% on Tuesday after the company sharply lowered its 2025 outlook for both sales and operating profit growth, which will ultimately impact its earnings per
Mission Produce Exhibits Valuation Premium: Time to Buy Now or Wait?
Mission Produce, Inc. AVO stock has gained momentum recently, driven by progress on key strategic initiatives aimed at strengthening customer relationships across products and global markets
TransAlta (TAC) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, TransAlta Corporation (TAC) is looking like an interesting pick, as it just reached a key level of support. TAC's 50-day simple moving average crossed above its 200-day
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 29.2% over the past four weeks, the stock looks well positioned for a trend reversal as it
Does Genius Sports Limited (GENI) Have the Potential to Rally 26.06% as Wall Street Analysts Expect?
Shares of Genius Sports Limited (GENI) have gained 0.7% over the past four weeks to close the last trading session at $10.17, but there could still be a solid upside left in the stock if short-term
Wall Street Analysts See a 30.18% Upside in Aris Mining Corporation (ARMN): Can the Stock Really Move This High?
Aris Mining Corporation (ARMN) closed the last trading session at $7.19, gaining 5.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Does Nomad Foods (NOMD) Have the Potential to Rally 37.22% as Wall Street Analysts Expect?
Nomad Foods (NOMD) closed the last trading session at $17.49, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Believe HNI (HNI) Could Rally 32.65%: Here's is How to Trade
HNI (HNI) closed the last trading session at $51.83, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
Shares of Tango Therapeutics, Inc. (TNGX) have gained 18.7% over the past four weeks to close the last trading session at $6.46, but there could still be a solid upside left in the stock if
TEMENOS GROUP (TMSNY)'s Technical Outlook is Bright After Key Golden Cross
TEMENOS GROUP (TMSNY) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMSNY's 50-day simple moving average broke out above its
Wall Street Analysts Believe Montrose Environmental (MEG) Could Rally 31.31%: Here's is How to Trade
Shares of Montrose Environmental (MEG) have gained 2.1% over the past four weeks to close the last trading session at $22.39, but there could still be a solid upside left in the stock if short-term
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Prime Medicine, Inc. (PRME) could be a good stock pick from a technical perspective. PRME recently experienced a "golden cross" event, which saw its 50-day


